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Dopamine is transported into synaptic vesicles by the vesicular monoamine transporter (VMAT2; SLC18A2). Disruption of
dopamine storage has been hypothesized to damage the dopamine neurons that are lost in Parkinson’s disease. By disrupting
vesicular storage of dopamine and other monoamines, we have created a progressive mouse model of PD that exhibits
catecholamine neuron loss in the substantia nigra pars compacta and locus coeruleus and motor and nonmotor symptoms. With
a 95% reduction in VMAT2 expression, VMAT2-deﬁcient animals have decreased motor function, progressive deﬁcits in olfactory
discrimination, shorter latency to behavioral signs of sleep, delayed gastric emptying, anxiety-like behaviors at younger ages, and
a progressive depressive-like phenotype. Pathologically, the VMAT2-deﬁcient mice display progressive neurodegeneration in the
substantia nigra (SNpc), locus coeruleus (LC), and dorsal raphe (DR) coupled with α-synuclein accumulation. Taken together,
these studies demonstrate that reduced vesicular storage of monoamines and the resulting disruption of the cytosolic environment
may play a role in the pathogenesis of parkinsonian symptoms and neurodegeneration. The multisystem nature of the VMAT2-
deﬁcient mice may be useful in developing therapeutic strategies that go beyond the dopamine system.
1.Introduction
Parkinson’s disease (PD) is a devastating neurodegenera-
tive disease and is characterized by a preferential loss of
dopamine neurons. PD is distinguished by the cardinal
symptoms of resting tremor, rigidity, bradykinesia, and
postural instability [1–3]. The incidence of PD is positively
correlated with age; there is a greater than 40-fold increase in
prevalence between the ages of 55 and 85 [3]. Approximately
5–10% of PD patients have a familial form of Parkinsonism
with either an autosomal dominant or autosomal recessive
patternofinheritance.Thesefamilialformsarecharacterized
by an age of onset before 40 years and a slowly progressive
course [4]. Pathogenic changes in PD are extensive and,
in addition to the loss of dopaminergic neurons in the
substantia nigra pars compacta (SNpc) and loss of striatal
innervation, include degeneration of the norepinephrine
(NE) neurons of the locus coeruleus (LC), serotonin (5-HT)
neurons of the raphe nuclei, the dorsal motor nucleus of
the vagus, and the peripheral autonomic nervous system,
among others [3, 5, 6]. Furthermore, Lewy body pathology
can also be found in the LC, nucleus basalis of Meynert,
hypothalamus, cerebral cortex, and in components of the
peripheral nervous system [2, 3, 7]. As the acknowledgement
of pathology associated with PD expands, symptoms beyond
the cardinal motor phenotype are also more commonly rec-
ognized, including hyposmia, sleep disturbances, gastroin-
testinal dysfunction, anxiety, depression, and autonomic
disturbances [8, 9]. The onset of these nonmotor symptoms
typically comprise a prodromal phase of the disease, which2 Parkinson’s Disease
c a nl a s ta n y w h e r ef r o maf e wy e a r st od e c a d e s .T h e s e
symptoms often play a large role in the quality of life and
disease etiology, and highlight the need to be more vigilant
as we look beyond a dopamine centric view and broaden our
understanding of PD pathogenesis. In doing so, targets for
therapeuticinterventionmayberevealedandprovideamore
comprehensive view of the disorder.
Abnormalities with monoaminergic handling and neu-
rotransmission are associated with a number of neurolog-
ical disorders, in addition to PD, such as schizophrenia,
depression, and drug addiction. Although the etiopatho-
genesis of PD remains unclear, it has been hypothesized
that the mishandling of DA as well as other monoamines
could underlie disease development. In this regard, many
researchers have proposed that the accumulation of cytosolic
DA has the ability to induce cytotoxicity with age; however,
the long-term toxicity of DA in vivo has only recently
been ﬁrmly established [10]. Many chemical models of PD,
such as 6-OHDA, manipulate the oxidative environment of
dopaminergic neurons to induce cell death. The endogenous
generation of reactive oxygen species (ROS), resulting from
both metabolism of monoamines in the cytosol and auto-
oxidation of monoamines, has been implicated as a mediator
in the pathophysiology of PD [10, 11]. However, physiolog-
ically, neurons have many safeguards to maintain neuronal
health and protect against degeneration.
The vesicular monoamine transporter 2 (VMAT2) is
one such custodian that functions to regulate the cytosolic
environment of the neuron, protecting it from endogenous
and exogenous toxins. Localized on vesicular membranes in
neurons, VMAT2 acts to accumulate cytosolic monoamines
into synaptic vesicles after they have been synthesized from
their precursors for regulated exocytotic release [12]. The
sequestration of monoamines is important for maintenance
of normal neurotransmission and also acts to keep intracel-
lular levels of the monoamines below potentially toxic levels
[13,14].VMAT2isa12-transmembranedomainH+-ATPase
antiporter, which uses an electrochemical gradient to drive
transport; two protons are exchanged for one monoamine
molecule [13, 15, 16]. VMAT2 has a similar selectivity for all
monoamines and is present throughout the central nervous
system and in the periphery in mast cells and platelets.
Phylogenetically, VMAT2 is a member of the solute carrier
protein family and the toxin-extruding antiporter (TEXAN)
gene family, which includes bacterial resistance genes [17,
18]. Moreover, VMAT2 contains sequence homology and
functional similarities to the major facilitator superfamily
of drug resistance transporters; many researchers have
hypothesized that VMAT2 has evolved to serve an analogous
role in eukaryotic systems by providing a mechanism to
sequester and clear toxins from the cell [19, 20]. Thus,
vesicular sequestration serves a dual purpose: preventing the
interaction of toxins with molecular machinery and limiting
exposure of neighboring cells to the toxin. In fact, VMAT2
was partly identiﬁed via its ability to confer resistance
to the dopaminergic toxin 1-methyl-4-phenylpyridinium
(MPP+), which is commonly used to induce a Parkinsonian
p h e n o t y p ei nm i c e[ 14]. The level of VMAT2 expression is
essential to proper monoaminergic handling, as it regulates
boththesizeofthevesicularmonoaminepoolandinﬂuences
the availability of monoamines in the cytosol, inﬂuencing
cellular susceptibility to oxidation [14]. The monoamines,
particularly DA and norepinephrine (NE) have the ability to
spontaneously oxidize in the cytosol, potentially damaging
cellular machinery [21].
2. VMAT2 andPD
Evidence for the monoamine theory of PD surfaced as
early as the 1950s but has not begun to be fully appre-
ciated until recently. Reserpine, an inhibitor of vesicular
monoamine transport, was ﬁrst introduced as a potent
antihypertensive drug [22]. Reserpine acts by depleting cells
of their monoamine stores; however, it is not selective for the
periphery and aﬀects the central nervous system as well [22,
23]. Patients who took reserpine chronically began to display
lethargy similar to that seen in depression, contributing
to the monoamine hypothesis of aﬀective disorders [22].
Furthermore, treatment with reserpine also reproduced
many of the deﬁcits observed in PD, including a decrease
in locomotor activity, akinesia, L-DOPA responsive stride
length, a depressive-like phenotype, and cognitive decline
[24–27]. Acute depletion of monoamine stores was found to
reproduce a similar symptom proﬁle as mice dosed with the
commonly used MPTP model of PD.
Theoretically, the loss of VMAT2 function within the
neuron would be associated with a reduction in vesicular
sequestration of monoamines, a concomitant accumulation
of cytosolic monoamines, depletion of striatal monoamines,
and the development of a Parkinsonian phenotype. It is
thought that together with the dopamine transporter (DAT),
VMAT2 may be able to modulate susceptibility to neu-
rodegeneration [20, 28]. There has been much speculation
about the role of VMAT2 in mediating eﬃcient clearance
of DA in those populations vulnerable to neurodegener-
ation [28, 29]. To this end, a positive correlation exists
between VMAT2 expression levels and regions of the brain
spared from Parkinsonian degeneration. For example, the
caudate and putamen have higher DAT expression relative
to VMAT2, consequently incurring more damage than other
monoaminergic areas of the brain like the hypothalamus,
which has high levels of VMAT2 relative to DAT [20]. In vivo
imaging and postmortem-binding studies displayed marked
reductions in VMAT2 immunoreactivity in the caudate,
putamen, and nucleus accumbens of PD brains [30, 31].
Interestingly, a gain of function haplotype of VMAT2 was
found to be protective against the development of PD
in humans [32]. Despite these data, it is still unclear if
reductions in VMAT2 are a contributor to or a consequence
of PD.
VMAT2 has been directly implicated with a pathological
hallmark of PD: α-synuclein. This key component of Lewy
bodies has been found to bind and permeabilize vesicles,
potentially causing leakage of monoamines into the cytosol
[33]. This has been hypothesized to be mediated via a direct
interaction between VMAT2 and α-synuclein, disrupting
synaptic vesicle dynamics [34]. Moreover, overexpression ofParkinson’s Disease 3
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Figure 1: VMAT2-deﬁcient animals display impaired stride length at older ages. (a) No deﬁcits in forepaw stride length were apparent at
12 or 18 months of age in VMAT2-deﬁcient mice. At 28 months of age, VMAT2-deﬁcient mice display motor deﬁcits as measured by inked
paw stride length. Results represent average stride length (cm) ± SEM for 4–6 animals per genotype, ∗∗P<. 01. (b) Representative forepaw
stride lengths for VMAT2 WT and deﬁcient mice at 12 and 28 months of age.
α-synuclein causes the downregulation of VMAT2 protein in
vitro, triggering increases in cytosolic DA and ROS [33, 35].
Taken together with evidence from oxidative stress studies,
these data demonstrate that the perturbation of VMAT2 can
create an environment conducive to PD-related cell damage
and pathology.
3.GeneticManipulationof VMAT2
3.1. VMAT2 Knockout Mice. In order to investigate the exact
role of VMAT2 in monoaminergic signaling several lines of
transgenicVMAT2micehavebeengenerated.Unfortunately,
complete deletion of the VMAT2 gene resulted in an animal,4 Parkinson’s Disease
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Figure 2: Timeline of Parkinsonian features observed in the VMAT2-deﬁcient mice from 2–30 months of age. Symptoms or pathology
indicated by a solid colored box did not increase in severity as the mice aged. All boxes end at the last age the symptom or pathology was
measured.Behavioralphenotypes:reductionsinlocomotoractivityandlatencytobehavioralsignsofsleepwereﬁrstobservedat2monthsof
age and were found to persist until their last measurements at 6 months of age and 18 months of age, respectively. Gastric emptying was ﬁrst
measured at 2 months of age, and increased in severity until the last time point at 18 months of age. Hyposmia began at 4 months, with full
anosmia at 6 months of age and persisting until the last evaluation at 18 months. Anxiety-like behavior was ﬁrst assessed at 4 months of age,
persisting until 6 months of age. Even though depressive-like behaviors were measured at 4–6 months of age, presence of a depressive-like
phenotype was not detected until 12 months of age, lasting until 15 months of age. Finally, reductions in forepaw stride length were not seen
until 27 months, reaching full severity at 30 months of age. Neurochemical pathology: evidence of oxidative damage was ﬁrst observed
through the formation of cysteinyl adducts at 2 months, which were still present at 12 months. Protein carbonyls and 3-nitrotyrosine
formation did not occur until 12 months of age. Accumulation of α-synuclein began at 18 months with evidence remaining until 24 months
of age. Loss of striatal DAT expression measured immunohistochemically began at 6 months of age progressing in severity until 22 months
of age. Reductions in striatal TH expression begin at 18 months of age, reaching maximal severity at 30 months. Degeneration of the LC
starts at 12 months of age in the VMAT2-deﬁcient animals, preceding nigral loss, which does not begin until 18 months of age.
which moved little, fed poorly, and died within a few days
after birth [36, 37], most likely a consequence of signiﬁcantly
reduced monoamine concentrations required for proper
monoaminergicsignaling.Inlightofthislethality,important
information concerning the role of VMAT2 in monoamine
neurotransmission was gleaned in vitro. For example, it was
determined that VMAT2 is a key determinant of quantal
release from monoaminergic cells, as levels were severely
reduced or absent from transgenic cultures. Moreover, these
data provided further evidence for the importance of presy-
naptic storage and release of monoamines for postsynaptic
receptor responsiveness [36, 37].
Although the VMAT2 KO mice do not survive into
adulthood, their creation also yielded mice that are het-
erozygous for VMAT2 (VMAT2 HT). Unlike the VMAT2
KO mice, the VMAT2 HTs are fully viable into adulthood,
display a 50% reduction in VMAT2 expression, and were
physiologically similar to their wildtype littermates [38].
Althoughreportshavevaried,overalltheVMAT2HTsappear
to have a signiﬁcant reduction in monoamines, perceived to
be a consequence of reduced vesicular storage capacity [37–
40]. Behaviorally, the VMAT2 HT mice perform normally in
passive avoidance and locomotor activity tests, but display
a depressive-like phenotype including anhedonia, locomotor
retardation, and sensitivity to stress [38, 41]. This phenotype
is ameliorated with the administration of antidepressants
such as imipramine, ﬂuoxetine, and bupropion, suggesting a
combined involvement of all three monoamine neurotrans-
mitters [41].
When challenged with various exogenous toxicants, the
V M A T 2H T sb e g i nt om a n i f e s td e ﬁ c i t sd u et or e d u c e d
vesicular storage capacity. Methamphetamine causes greater
neurotoxicityintheVMAT2HTmicecomparedtowild-type
animals, with signiﬁcant reductions in DA, DA metabolites,
and DAT [42]. These ﬁndings were coupled with a less
pronounced increase in extracellular DA, suggesting thatParkinson’s Disease 5
cytosolic DA is the prevailing factor in the potentiation
of methamphetamine toxicity observed in the mice [42].
Behaviorally, amphetamine produced enhanced locomotor
activity but reduced reward as measured by conditioned
place preference [38]. In addition to the amphetamines,
VMAT2 HT mice were also found to be acutely more
sensitive to the eﬀects of the Parkinsonian drug MPTP.
Presumably, due to their reduced capacity to sequester
MPP+, VMAT2 HT mice undergo twice the dopaminergic
cell loss observed in wild-type animals, accompanied by
m a r k e r so fs t r i a t a ld a m a g es u c ha sr e d u c t i o n si nD A ,D A T
and increased glial ﬁbrillary acidic protein (GFAP) mRNA
[38, 39]. Although the VMAT2 HT mice did not display
any overt signs of Parkinsonism or PD-like neuropathology,
they do exhibit an increased susceptibility to MPTP toxicity
and thus, researchers postulated that the mice may be
useful in teasing out the mechanisms of L-DOPA toxicity.
It was found that primary DA neurons harvested from
VMAT2 HTs were more vulnerable to L-DOPA than wild-
type neurons; decreased VMAT2 activity might attenuate
L-DOPA eﬃcacy by augmenting endogenous dopaminergic
toxicity[43].However,theseresultswerenotobservedinvivo
[40]. Despite the absence of a clear link between vesicular
storage and L-DOPA-induced dopaminergic dysfunction,
manipulating VMAT2 still produces an increased sensitivity
to parkinsonian toxins and signs of depression, one of the
most prevalent nonmotor symptoms associated with PD.
3.2. The VMAT2 Hypomorph Mouse. As investigators con-
tinued to ponder the role of VMAT2 in the pathogenesis
of PD, further perturbation of the gene was necessary
to produce a more profound disruption of monoamine
storage than previously achieved with the VMAT2 HT mice.
This perturbation was manifested in a line of mice that
expressed only 5% of the VMAT2 protein. It is important
to note that unlike the previous VMAT2 KO and HT mice,
the KA1 line was created through gene targeting using a
completely diﬀerently strain of mouse, which was found to
be α-synuclein null [44]. Both the hypomorphic VMAT2
allele and the α-synuclein-null allele were both unintended
consequences of an attempt to make VMAT2 knockout mice,
but notably serendipitous to the PD ﬁeld (see below). Unlike
the VMAT2 KO mice, the KA1 mice are fully viable into
adulthood with the absence of gross physical defects [45].
The survival of these KA1 mice allowed the examination
of the eﬀects of reduced vesicular storage over a lifetime,
in addition to the study of the nuances of vesicular uptake
mechanisms; whereas, both VMAT2 KO and chronically
reserpinized animals are not amenable to studying the eﬀects
of aging on monoamine packaging defects.
Although no VMAT2 expression was detected in these
mice through immunohistochemistry or in situ hybridiza-
tion, residual VMAT2 was observed using western blotting
approximating a 95% reduction [10, 45]. Consequently,
there were general reductions in tissue levels of the major
monoamines, DA, NE, and 5-HT reduced by 92%, 87%, and
82%, respectively, which became progressively worse with
age, accompanied by increased monoamine turnover and
reduced DA availability in terminal and cell body regions
of the SNpc and ventral tegmental area (VTA) [45, 46]. In
addition to the reduction of monoamines, the KA1 mice
were also found to have altered striatal neurotransmission
and signaling. Although levels of DAT mRNA, protein, and
activityandD1/D2 receptorexpressionremainedunchanged,
electrically stimulated DA release was dramatically reduced
by approximately 70% compared to age-matched wild-type
animals [47, 48]. As demonstrated in the VMAT2 KO mice,
a decrease in striatal DA release this dramatic is indicative
of smaller vesicular DA stores due to a reduction in VMAT2
expression [47]. Considering that electrically stimulated DA
release is absent in VMAT2 KO neurons, these data suggest
considerableintraneuronalcompensationforthe95%deﬁcit
in VMAT2 [37]. Moreover, due to the disproportionate
decrease in DA release compared to the reduction in VMAT2
expression, it is possible to conceive that in wild-type
neurons, not all VMAT2 protein is required to ﬁll vesicles
for exocytotic release; many transporters may, in fact, act as a
reserve[47].Additionally,eventhoughnocompensationwas
seen through changes in DA receptor expression, ablating
VMAT2 by 95% did induce a supersensitization of the D2/D3
autoreceptors and downregulated phosphorylation of tyro-
sine hydroxylase (TH) at serine residues (Ser19, Ser31, and
Ser40), which are critical for catechol feedback inhibition
[46]. Finally, the KA1 mice were found to downregulate
substance P while upregulating enkephalin, allowing for the
possibility of abnormalities in organization of DA-mediated
signaling via both the direct and indirect pathways [45, 48].
Taken together, these data provide further evidence for the
role of VMAT2 expression in regulating the size of both
vesicular and cytosolic DA pools within the CNS, thus
inﬂuencing extracellular neurotransmission [46, 47].
With the abundance of changes in striatal neurotrans-
mission, the KA1 mice were tested for the presence of a
behavioral phenotype that correlated with PD. As in reser-
pinizedanimals,reductionsinVMAT2intheKA1micecause
a general decrease in locomotor activity [45]. At an early
age, the KA1 mice demonstrated a signiﬁcant impairment
in motor coordination, independent of motivational factors,
as measured by the challenging beam traversal and rotarod,
which becomes progressively more severe with age [45, 46].
However, they exhibit normal reactivity in novelty place
preference task [45]. As expected, the KA1 are exquisitely
sensitive to acute doses of MPTP and amphetamine. When
exposed to amphetamine, the KA1 mice display an increase
in stereotypic behaviors and abnormalities in DA release [45,
47]. Similarly, the KA1 have a lower threshold to MPTP tox-
icity, demonstrating dopaminergic damage and locomotor
deﬁcits [45]. Conversely, when L-DOPA is administered, the
KA1 mice exhibit locomotor hyperactivity and amelioration
of deﬁcits in motor coordination and balance [45, 46].
Interestingly, despite the presence of both striatal dopamine
deﬁciencyandamotorphenotype,whenassessedforsignsof
Parkinsonian degeneration, no evidence of DA cell loss was
found at any age [46]. However, as mentioned above, these
micecontainaspontaneous chromosomaldeletion spanning
the α-synuclein gene locus [44–47]. The lack of this note-
worthy gene may account for the absence of degeneration
as cytosolic dopamine and other monoamines have been6 Parkinson’s Disease
proposed to inhibit α-synuclein ﬁbrillization by oxidatively
ligating to α-synuclein [49, 50], thus retaining α-synuclein
in its neurotoxic protoﬁbril conformation. Assuming that
protoﬁbrils are the pathogenic species, a 95% decrease of
VMAT2 in neurons should have lethal implications, causing
the cytosolic auto-oxidation of catecholamines to increase,
amplifying protoﬁbril concentration. To answer the question
morefully,itwasnecessarytointroducetheα-synucleingene
into the mice with low VMAT2 expression.
3.3. Perfected Perturbation: VMAT2-Deﬁcient Mice. Al-
though the availability of the VMAT2 KA1 mice provided an
extremely useful model with which to further examine the
importance of DA handling, the complete ablation of such
a ubiquitous protein such as α-synuclein severely limited
the utility of these mice from the perspective of dopamine
handling and PD pathogenesis. Fortunately, the Emory
colony of KA1 mice contained animals that were heterozy-
gous for both the VMAT2 and α-synuclein alleles. Through
diligent breeding, all traces of the α-synuclein mutation were
eliminated from the KA1 line of mice yielding the VMAT2-
deﬁcient mice. Consistent with previous reports of genetic
and pharmacological reductions of VMAT2, striatal DA
levels were reduced by 85% in VMAT2-deﬁcient mice with a
concomitantreductioninthemetabolites,DOPACandHVA;
VMAT2-deﬁcient mice also exhibited an age-dependent
decline in DA [10]. Several intraneuronal compensatory
mechanisms were also observed in the VMAT2-deﬁcient
mice including an increase in TH activity, increased DA
turnover, and an age-dependent decline in DAT expression
and activity [10]. Additionally, several markers of oxidative
stress and damage were observed in the VMAT2-deﬁcient
mice. Although cysteinyl-DA was undetectable due to the
reduced basal levels of DA and increased DA turnover,
free cysteinyl-DOPA and DOPAC adducts were signiﬁcantly
increased at both 2 and 12 months of age; protein carbonyls
and 3-nitrotyrosine did not manifest until 12 months of
age, demonstrating that neuronal oxidative stress became
progressively worse with age [10]. The chronic dysregulation
of DA within VMAT2-deﬁcient neurons began to contribute
to neuronal degeneration in older animals, as evidence of cell
death was seen through silver deposition and a progressive
loss of TH-positive neurons within the SNpc [10].
Behaviorally, VMAT2-deﬁcient mice exhibit many of the
Parkinsonian motor phenotypes. Beginning at 2 months of
age, VMAT2-deﬁcient mice have general deﬁcits in novelty-
induced locomotor activity, which is L-DOPA responsive
(Table 1)[ 10]. Interestingly, in the VMAT2-deﬁcient mice
it has been observed that the major motor deﬁcits do
not appear until 28 months of age, coinciding with the
most severe nigral cell loss (Taylor and Miller, unpub-
lished observations). Compared to age-matched wild-type
littermates, VMAT2-deﬁcient mice do not demonstrate a
deﬁcit in forepaw stride length until 28 months of age; this
behavior is thought to mimic the shuﬄing gait observed in
PD patients [51] (Figure 1). This behavior is also L-DOPA
responsive, establishing that the motor phenotype is due to
dopamine insuﬃciency. Combined with the dopaminergic
characterization of these mice, these data reveal that reduced
vesicular storage of DA is enough to induce Parkinsonian
neurodegeneration.
Mounting evidence for degeneration of the locus
coeruleus (LC) in human PD highlights the importance of
expanding the focusof researchfrom the nigrostriatal system
in order to expose the deﬁcits in other neurotransmitter
systems [3, 7, 52–55]. Beginning at 18 months of age, the
VMAT2-deﬁcient mice displayed a mild reduction in TH
staining in the SNpc and striatum, which increased mod-
erately with age [10, 56]. More dramatic reductions in TH
staining were observed in the locus coeruleus (LC) at 18, 24,
and 30 months of age [56]. This pattern of neuronal loss was
veriﬁed using unbiased stereological counts, demonstrating
that neuronal loss in the LC precedes nigral loss in the
VMAT2-deﬁcient mice [56]. The LC of VMAT2-deﬁcient
mice undergoes a much more rapid decline from 12 to 18
months of age, with an overall 72% neuronal loss from 6-
30 months of age [56]. The SNpc of the VMAT2-deﬁcient
mice does not start to degenerate until 18 months of age,
with an overall 59% cell loss, similar to the loss observed in
humans [56]. Taken together, these data suggest that, unlike
other chemical and genetic models of PD, the LC undergoes
a much more severe degeneration than the SNpc in the
VMAT2-deﬁcient mice.
In classical PD, motor disturbances do not present
clinically until approximately 70–80% of striatal dopamine
and 40–50% of nigral cell bodies have already been lost;
however, other nonmotor symptoms are evident before the
onset of motor disturbances. These include, but are not
limited to, hyposmia/anosmia, gastrointestinal disturbances,
sleep abnormalities, autonomic dysfunction, anxiety, and
depression [52, 57]. It is probable that other neurotrans-
mitters such as NE and 5-HT signiﬁcantly contribute to
these symptoms, as both the LC and raphe nucleus have
also been shown to degenerate in PD, in addition to the
SNpc [3, 54, 55]. With the pathology observed in the major
monoaminergic systems of the VMAT2-deﬁcient mice, the
presence of nonmotor phenotypes would not be unlikely.
Olfactory disturbances are one of the ﬁrst nonmotor
symptoms observed in PD; patients have demonstrated
impairments in odor detection, diﬀerentiation, and iden-
tiﬁcation [58–60]. Moreover, this nonmotor symptom is
not responsive to traditional dopaminergic therapies [61].
When subjected to a battery of olfactory discrimination tests
at various ages, VMAT2-deﬁcient animals were unable to
discriminate between two blocks (one scented with bedding
from their home cage and one scented from the cage of a
foreign animal of the same sex), and consequently displayed
no preferential exploration of either block [62]. VMAT2
wild-type animals displayed preferential exploration of the
foreign-scentedblockatallagestested[62].Whenchallenged
in a similar test of olfactory acuity using scents commonly
used on the University of Pennsylvania Smell Identiﬁcation
Test (UPSIT), VMAT2-deﬁcient mice again showed no
preferential exploration of the novel scent as compared with
water, whereas VMAT2 wild-type animals spent more time
investigating the novel scent [62]. The olfactory deﬁcit is not
corrected by L-DOPA treatment in human PD patients, nor
is it eﬀective in our mice (Table 1). To ensure there was notParkinson’s Disease 7
Table 1: Summary of L-DOPA responsive Parkinsonian symptoms.
Behavior
L-DOPA
responsive in
VMAT2-Deﬁcient?
L-DOPA
responsive in
humans?
Olfactory Discrimination No No
Sleep Latency Yes No
Anxiety Suggested Variable
Depression Yes Variable
Gastrointestinal
Dysfunction No No
Locomotor Activity Yes Yes∗
Forepaw Stride Length Yes Yes∗
∗Falling, freezing of gait, and postural instability are all L-DOPA unrespon-
sive.
a problem in general sensory perception, mice were tested
for nonolfactory sensory deﬁcits. VMAT2-deﬁcient animals
showed no deﬁcits in response to tactile stimulation, quinine
taste aversion, trigeminal nerve function, muscle strength, or
visual acuity [62].
In order to investigate behavioral sleep disturbances
in the VMAT2-deﬁcient mice, sleep latency tests were
conducted in VMAT2 wild-type and deﬁcient mice during
their circadian nadir. Beginning at 2 months of age, VMAT2-
deﬁcient mice show a shorter latency to behavioral signs of
sleep compared to age-matched wild-type controls, which is
responsive to an acute dose of L-DOPA (Table 1)[ 62]. The
circadian activity of VMAT2-deﬁcient animals is also signif-
icantly lower than that of age-matched wild-type controls
at younger ages, but follows normal patterns compared to
wild-type animals [62]. VMAT2-deﬁcient animals were next
behaviorallyexaminedforgastricemptyingat2,6,12,and18
months of age, as gastrointestinal dysfunction in PD occurs
in over 70% of PD patients [9, 57]. Solid gastric emptying
was signiﬁcantly delayed overall in VMAT2-deﬁcient mice,
withanincreasedstoolfrequency,indicatingafairamountof
gastrointestinal dysfunction in the VMAT2-deﬁcient animals
[62]. As in humans, an acute dose of L-DOPA did not
ameliorate the gastrointestinal dysfunction observed in these
animals (Table 1).
Disruptions in DA, NE, and 5-HT neurotransmission,
includingdegenerationoftheLCandDR,havebeenfoundin
PD patients with anxiety and/or depression; similar pathol-
ogy has been observed in the VMAT2-deﬁcient mice indi-
cating the possibility for both anxiety-like and depressive-
like phenotypes [9, 53, 62]. Moreover, the VMAT2 HT
mice have been previously found to display a depressive-like
phenotype [41]. Severe reduction of VMAT2 expression in
the VMAT2-deﬁcient mice was found to trigger both anxiety
and progressive depressive behavior. VMAT2-deﬁcient mice
showed a signiﬁcant increase in percentage of open arm time
in the elevated plus maze at 4–6 months of age, while the
increased immobility time in the forced swim and tail sus-
pensiontestsdidnotoccuruntil12monthsofage;suggesting
that anxiety precedes depressive symptoms in VMAT2-
deﬁcient animals and that the depressive-like phenotype is
progressive[62].Additionally,alowdoseofdesipraminethat
had no eﬀect in wild-type animals was able to normalize
immobility times in VMAT2-deﬁcient mice; similarly, an
acutedoseofL-DOPAwasalsoabletoamelioratedepressive-
like symptoms in the VMAT2-deﬁcient mice (Table 1)[ 62].
Despite the presence of many of the nonmotor symptoms
associated with PD in the VMAT2-deﬁcient animals, the
animals have not yet been tested for cognitive deﬁcits or
presence of autonomic dysfunction. The involvement of
multiple neurotransmitter systems and evidence from other
mouse models with noradrenergic degeneration suggests
that cognitive and cardiovascular deﬁcit may also be present
in the VMAT2-deﬁcient animals [63, 64].
4. Conclusions
As the VMAT2-deﬁcient mice have reduced levels of DA, NE,
and 5-HT, L-DOPA responsive motor deﬁcits, and almost
the full constellation of nonmotor symptoms, mice with
altered VMAT2 expression may represent a new model of
PD that encompasses many of the motor and nonmotor
symptoms, as well as the neurochemical pathophysiology
(Figure 2)[ 10, 41, 45, 62]. Moreover, most current models
of PD, genetic and chemical, represent a relatively short
disease progression. The average lifespan of a mouse is
two years; disease progression must reﬂect this because
sporadic PD, like Alzheimer’s disease, is a disease of aging.
The VMAT2-deﬁcient mice exhibit a high age dependency
coupled with a progressive behavioral decline (Figure 2).
The nigral and extranigral pathology combined with the
motor and nonmotor symptoms in the VMAT2-deﬁcient
mice strongly argue that the underlying pathogenesis of
human PD likely has some common features. For example,
many of the PARK genes have been shown to disrupt
properrecycling,traﬃcking,andreleaseofvesicles.Whilethe
mode of vesicular disturbance may diﬀer in individual PD
cases, disrupted vesicular function, whether it is via storage
or traﬃcking, of monoamines may represent a common
pathogenic mechanism. These mice demonstrate that it is
possible that PD pathogenesis represents more than altered
DA homeostasis; a global disruption of monoamine storage
and handling may be necessary to fully invoke the pathology
associated with the disease. Utilizing the VMAT2-deﬁcient
mice as a new model of PD, could potentially lead to new
adjunct therapeutic strategies, which complements current
dopamine replacement therapy, improving the quality of life
for many patients.
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